Literature DB >> 24638248

In vivo therapy monitoring of experimental rheumatoid arthritis in rats using near-infrared fluorescence imaging.

Sonja Vollmer1, Ines Gemeinhardt2, Axel Vater3, Beatrix Schnorr2, Jörg Schnorr2, Jan Voigt4, Bernd Ebert5.   

Abstract

An in vivo near-infrared fluorescence (NIRF) imaging technique is described for therapy monitoring of ankle joints affected by collagen-induced arthritis, a model of human rheumatoid arthritis. Arthritis was induced in rats by intradermal injections of collagen and Freund's incomplete adjuvant. For in vivo imaging, the nonspecific NIR dye tetrasulfocyanine (TSC) was used. Prior to and after treatment with a nonsteroidal anti-inflammatory drug, meloxicam, or analgesic drug, tramadol hydrochloride (which served as no-therapy control), normalized fluorescence intensities of each ankle joint were measured. Additionally, each ankle joint was characterized by clinical arthritis scoring and histopathology. Over a 3-week treatment period, a significant difference in disease progression between animals treated with meloxicam and tramadol hydrochloride was detected. A statistically significant improvement in ankle joint pathology from high- or moderate-grade to moderate- or low-grade upon meloxicam therapy, as determined by clinical evaluation, translated into a significant decrease in fluorescence intensity. In contrast, all arthritic joints of the no-therapy control group deteriorated to high-grade arthritis with high-fluorescence intensities in NIRF imaging.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24638248     DOI: 10.1117/1.JBO.19.3.036011

Source DB:  PubMed          Journal:  J Biomed Opt        ISSN: 1083-3668            Impact factor:   3.170


  1 in total

1.  Optical coherence tomography-guided laser microsurgery for blood coagulation with continuous-wave laser diode.

Authors:  Feng-Yu Chang; Meng-Tsan Tsai; Zu-Yi Wang; Chun-Kai Chi; Cheng-Kuang Lee; Chih-Hsun Yang; Ming-Che Chan; Ya-Ju Lee
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.